title: Symptomatic therapy in multiple sclerosis: Big pharma should do more-YES.
authors.affiliation: Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, Cerrahpasa, Turkey akselsiva@gmail.com.
authors.forename: Aksel
authors.initials: A
authors.lastname: Siva
authors.affiliation: Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, USA.
authors.forename: Orhun
authors.initials: O
authors.lastname: Kantarci
mesh_terms: D003072:Cognition Disorders / Q000209:etiology / Q000523:psychology; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000523:psychology